1
RNA modifications are enzymatic RNA base modifications that increase the RNA alphabet from the 4 canonical nucleotides to more than 140 (a brief overview of RNA modifications is available here: http://modo mics.genesilico.pl/modifications/ accessed 24 March 2017). Although the number of protein-encoding genes has remained relatively constant during evolution, the repertoire of RNA modifications has been increased substantially, which may account for the fine tuning of mRNA biogenesis observed in mammals and especially in humans. Among the most frequent RNA modifications are adenosine deamination and methylation. The adenosine deamination to inosine is a process called RNA editing and is catalysed by the adenosine deaminases acting on RNAs (ADARs). 2, 3 We have recently showed that ADAR1-mediated A-to-I RNA editing of cathepsin S (CTSS) regulates CTSS mRNA stability by controlling the recruitment of the stabilizing RNA-binding protein (RBP) HuR (ELAVL1) to the 3'-untranslated region (3'UTR) of cathepsin S mRNA, a mechanism that is associated with atherosclerotic heart disease. 4 ADAR1 p150 isoform expression and subsequently RNA editing is upregulated under pro-inflammatory conditions in vitro, as well as in patients with atherosclerosis, indicating that RNA editing may be a critical regulator of pro-inflammatory gene expression under stress conditions. 3 Further, HuR is known to stabilize a plethora of stress-regulated genes, a process that may be involved in stress-induced cardiomyopathy and in inflammatory vascular diseases, including coronary artery disease, acute coronary syndromes, peripheral arterial atherosclerotic disease and aortic aneurysm formation. However, whether other RNA modifications are involved in various mechanisms of cardiovascular disease remain yet unknown.
Adenosine methylation at the N6 position (m6A) is the most prominent reversible RNA modification in eukaryotic transcriptome and although it has been discovered 40 years ago, only in 2012 methodological advances from two pioneering works enabled the identification and characterization of RNA methylated sites throughout the transcriptome. 5, 6 As a result, an outburst of studies exploring the molecular functions of several RNA modifications has been triggered, contributing thus to the better understanding of RNA methylation in RNA metabolism and function (reviewed in 7 ). Part of these studies identified also the regulators of the mammalian m6A RNA modification. [8] [9] [10] [11] Specifically, they found that it is catalysed by a methyltransferase complex consisted of three crucial components, METTL3, METTL14, and WTAP (known as m6A writers), 8, 9 while it is reversed by the demethylases FTO and ALKBH5 (known also as m6A erasers).
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The recent report by Patil et al. 1 describes for the first time the role of RNA modifications, and especially of RNA methylation in molecular function of long non-coding RNAs (lncRNAs) which are transcripts longer that 200nts lacking protein-coding properties. 12 Specifically, RNA methylation controls the known function of the lncRNA XIST in transcriptional repression of the chromosome X 13 by recruiting certain m6A binding proteins that specifically interact with m6A-bearing sites (known as m6A readers). Utilizing advanced molecular biology methods including m6A individual-nucleotide resolution ultra-violet crosslinking and immunoprecipitation, the authors discovered 78 m6A sites across XIST showing that the lncRNA XIST is the highest methylated lncRNA in human cells. Further, they shed light into the mechanism that enabled the m6A RNA methylation of XIST, as well as they revealed the effect of m6A RNA methylation in lncRNA functions. Additionally, they stipulated certain RBPs, RNA-binding motif protein 15 (RBM15) and its paralogue RBM15B, that are essential for the recruitment of the methyltransfrase complex at XIST enabling its m6A RNA methylation. Moreover, the Professor Konstantinos Stellos currently works as an academic cardiologist at the Goethe University Hospital Frankfurt, Germany. He has followed a dual career path of a physician scientist treating patients with cardiovascular disease and studying novel mechanisms involved in the pathogenesis of atherosclerosis and its consequences. His laboratory (http://www.stelloslab.com) focuses on the discovery of RNA-based mechanisms including RNA editing that are critically involved in vascular homeostasis or in atherosclerotic heart disease. His research has been awarded with numerous prizes including the American Heart Association Young Investigator Award of the Council on Functional Genomics and Translational Biology. authors corroborated these findings by RBM15 and RBM15B or METTL3 loss-of-function studies which pointed towards the conclusion that absence of RNA methylation impairs XIST-mediated gene silencing. Further, the authors elegantly designated the magnitude of m6A methylation given that the m6A reader protein YTH domain containing 1 (YTHDC1), which preferentially recognizes m6A residues on XIST, is required for XIST function. These data reveal a previously unrecognized molecular mechanism of RNA modifications controlling lncRNAs functions. Nevertheless, the impact of RNA modifications including RNA methylation and RNA editing in the metabolism of the majority of their target mRNAs and lncRNAs remains elusive. Increasing evidence suggests a decisive role of lncRNAs in cardiovascular physiology and disease.
14 Therefore, the study by the Laboratory of Samie R. Jaffrey at the Cornell University, New York, opens new horizons in all research fields and may pave the way towards the development of new disease biomarkers and therapeutic strategies in cardiovascular disease. Specifically, RNA modifications may be hallmarks of disease development or disease prognosis, while in the era of genome editing, targeting specific modified nucleotides in RNA molecules may be an effective way to simultaneously target modified genes that are critically involved in disease. Further work on this research field is needed to elucidate the edited/modified transcriptome and its consequences for expression of genes that are known to be critical in the pathogenesis of cardiovascular disease.
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